Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:160-167
Published online before print January 2, 2003, doi: 10.1161/01.ATV.0000054658.91146.64
Published online before print January 2, 2003, doi: 10.1161/01.ATV.0000054658.91146.64
© 2003 American Heart Association, Inc.
Brief Review |
Cholesteryl Ester Transfer Protein
A Novel Target for Raising HDL and Inhibiting Atherosclerosis
From the Hanson Institute and the Department of Cardiology (P.J.B.), Royal Adelaide Hospital, Adelaide, Australia; the National Heart, Lung, and Blood Institute (H.B.B. Jr), National Institutes of Health, Bethesda, Md; the National Institute for Health and Medical Research and Hopital de la Pitie (M.J.C.), Paris, France; the Preventive Cardiology and Lipid Clinic (D.J.R.), University of Pennsylvania Medical Center, Philadelphia; the Mount Sinai Medical Center–Miami Heart Institute and the Departments of Medicine and Epidemiology and of Public Health (C.H.H.), University of Miami School of Medicine, Miami, Fla; and the Division of Molecular Medicine (A.R.T.), Department of Medicine, Columbia University, New York, NY.
Correspondence to Prof Philip J. Barter, The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney, Australia 2050. E-mail p.barter{at}hri.org.au
Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters from antiatherogenic HDLs to proatherogenic apolipoprotein B (apoB)–containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically antiatherogenic. Studies in rabbits, a species with naturally high levels of CETP, support the therapeutic potential of CETP inhibition as an approach to retarding atherogenesis. Studies in mice, a species that lacks CETP activity, have provided mixed results. Human subjects with heterozygous CETP deficiency and an HDL cholesterol level >60 mg/dL have a reduced risk of coronary heart disease. Evidence that atherosclerosis may be increased in CETP-deficient subjects whose HDL levels are not increased is difficult to interpret and may reflect confounding or bias. Small-molecule inhibitors of CETP have now been tested in human subjects and shown to increase the concentration of HDL cholesterol while decreasing that of LDL cholesterol and apoB. Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacological inhibition of CETP retards the development of atherosclerosis.
Key Words: HDL • LDL • reverse cholesterol transport • genetic CETP deficiency
This article has been cited by other articles:
 |
|
 |
|
  T. Koike, S. Kitajima, Y. Yu, Y. Li, K. Nishijima, E. Liu, H. Sun, A. B. Waqar, N. Shibata, T. Inoue, et al. Expression of Human ApoAII in Transgenic Rabbits Leads to Dyslipidemia: A New Model for Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2047 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Carvalho, R. Pereira, and Y. Shoenfeld Vaccination, atherosclerosis and systemic lupus erythematosus Lupus, November 1, 2009; 18(13): 1209 - 1212. [Abstract] [PDF]
|
|
|
|
|
|
D. Lakomy, C. Rebe, A.-L. Sberna, D. Masson, T. Gautier, A. Chevriaux, M. Raveneau, N. Ogier, A. T. Nguyen, P. Gambert, et al. Liver X Receptor-Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1923 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J., October 12, 2009; (2009) ehp399v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Moreno, J. Sanz, and V. Fuster Promoting Mechanisms of Vascular Health: Circulating Progenitor Cells, Angiogenesis, and Reverse Cholesterol Transport J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2315 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Hu, J. D. Dietz, C. Xia, D. R. Knight, W. T. Loging, A. H. Smith, H. Yuan, D. A. Perry, and J. Keiser Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition Endocrinology, May 1, 2009; 150(5): 2211 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Masson, X.-C. Jiang, L. Lagrost, and A. R. Tall The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis J. Lipid Res., April 1, 2009; 50(Supplement): S201 - S206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation, December 9, 2008; 118(24): 2506 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Koropatnick, J. Kimbell, R. Chen, J. S. Grove, T. A. Donlon, K. H. Masaki, B. L. Rodriguez, B. J. Willcox, K. Yano, and J. D. Curb A Prospective Study of High-Density Lipoprotein Cholesterol, Cholesteryl Ester Transfer Protein Gene Variants, and Healthy Aging in Very Old Japanese-American Men J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2008; 63(11): 1235 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bakhai Adipokines--targeting a root cause of cardiometabolic risk QJM, October 1, 2008; 101(10): 767 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Xiao, T. Watanabe, Y. Zhang, B. Trigatti, L. Szeto, P. W. Connelly, S. Marcovina, T. Vaisar, J. W. Heinecke, and G. F. Lewis Enhanced Cellular Uptake of Remnant High-Density Lipoprotein Particles: A Mechanism for High-Density Lipoprotein Lowering in Insulin Resistance and Hypertriglyceridemia Circ. Res., July 18, 2008; 103(2): 159 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. He, D. J. Greene, M. Kinter, and R. E. Morton Control of cholesteryl ester transfer protein activity by sequestration of lipid transfer inhibitor protein in an inactive complex J. Lipid Res., July 1, 2008; 49(7): 1529 - 1537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Lackner, L. J. Cohn, R. P. Dullaart, A. C. M. Kobold, A. van Tol, P. Barter, C. L. Shear, J. H. Revkin, and D. J. Rader Torcetrapib and Coronary Events N. Engl. J. Med., April 24, 2008; 358(17): 1862 - 1864. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Cardiovasc Res, March 1, 2008; 77(4): 732 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Valkenburg, R. P. M. Steegers-Theunissen, H. P. M. Smedts, G. M. Dallinga-Thie, B. C. J. M. Fauser, E. H. Westerveld, and J. S. E. Laven A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Jensen, K. J. Mukamal, K. Overvad, and E. B. Rimm Alcohol consumption, TaqIB polymorphism of cholesteryl ester transfer protein, high-density lipoprotein cholesterol, and risk of coronary heart disease in men and women Eur. Heart J., January 1, 2008; 29(1): 104 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Charlton-Menys and P. N. Durrington Human cholesterol metabolism and therapeutic molecules Exp Physiol, January 1, 2008; 93(1): 27 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter, M. Caulfield, M. Eriksson, S. M. Grundy, J. J.P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.-C. Tardif, D. D. Waters, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events N. Engl. J. Med., November 22, 2007; 357(21): 2109 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J. Lipid Res., June 1, 2007; 48(6): 1263 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eichinger, N. M. Pecheniuk, G. Hron, H. Deguchi, M. Schemper, P. A. Kyrle, and J. H. Griffin High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism Circulation, March 27, 2007; 115(12): 1609 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease Eur. Heart J., January 1, 2007; 28(1): 5 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gautier, U. J. F. Tietge, R. Boverhof, F. G. Perton, N. Le Guern, D. Masson, P. C. N. Rensen, L. M. Havekes, L. Lagrost, and F. Kuipers Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein J. Lipid Res., January 1, 2007; 48(1): 30 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Davidson, J. M. McKenney, C. L. Shear, and J. H. Revkin Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1774 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Sirtori HDL and the progression of atherosclerosis: new insights Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F4 - F9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barter Options for therapeutic intervention: how effective are the different agents? Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F47 - F53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fazio and M. F. Linton Sorting Out The Complexities of Reverse Cholesterol Transport: CETP Polymorphisms, HDL, and Coronary Disease. J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3273 - 3275. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Casquero, J. A. Berti, A. G. Salerno, E. J. B. Bighetti, P. M. Cazita, D. F. J. Ketelhuth, M. Gidlund, and H. C. F. Oliveira Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice J. Lipid Res., July 1, 2006; 47(7): 1526 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. Hugh, R. Barrett, F. K. Welty, A. Faruqi, M. L. Wolfe, C. Nartsupha, A. G. Digenio, et al. Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1350 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuchel and D. J. Rader Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis? Circulation, May 30, 2006; 113(21): 2548 - 2555. [Full Text] [PDF]
|
|
|
|
|
|
P. C.N. Rensen and L. M. Havekes Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport? Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 681 - 684. [Full Text] [PDF]
|
|
|
|
|
|
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Clark, R. B. Ruggeri, D. Cunningham, and M. J. Bamberger Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action J. Lipid Res., March 1, 2006; 47(3): 537 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter and J. J.P. Kastelein Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. LIINAMAA, M. L. HANNUKSELA, M. E. RAMET, and M. J. SAVOLAINEN DEFECTIVE GLYCOSYLATION OF CHOLESTERYL ESTER TRANSFER PROTEIN IN PLASMA FROM ALCOHOL ABUSERS Alcohol Alcohol., January 1, 2006; 41(1): 18 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Curtiss, D. T. Valenta, N. J. Hime, and K.-A. Rye What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport? Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dumont, T. Gautier, J.-P. P. de Barros, H. Laplanche, D. Blache, P. Ducoroy, J. Fruchart, J.-C. Fruchart, P. Gambert, D. Masson, et al. Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI J. Biol. Chem., November 11, 2005; 280(45): 38108 - 38116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. E. Groot, N. J. Pearce, J. W. Yates, C. Stocker, C. Sauermelch, C. P. Doe, R. N. Willette, A. Olzinski, T. Peters, D. d'Epagnier, et al. Synthetic LXR agonists increase LDL in CETP species J. Lipid Res., October 1, 2005; 46(10): 2182 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Frisdal, A. H.E.M. Klerkx, W. L. Goff, M. W.T. Tanck, J.-P. Lagarde, J. W. Jukema, J. J.P. Kastelein, M. J. Chapman, and M. Guerin Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study Hum. Mol. Genet., September 15, 2005; 14(18): 2607 - 2618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ishihara, T. Kujiraoka, T. Iwasaki, M. Nagano, M. Takano, J. Ishii, M. Tsuji, H. Ide, I. P. Miller, N. E. Miller, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration J. Lipid Res., September 1, 2005; 46(9): 2015 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Bisoendial, G. K. Hovingh, K. El Harchaoui, J. H.M. Levels, S. Tsimikas, K. Pu, A. E. Zwinderman, J. A. Kuivenhoven, J. J.P. Kastelein, and E. S.G. Stroes Consequences of Cholesteryl Ester Transfer Protein Inhibition in Patients With Familial Hypoalphalipoproteinemia Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): e133 - e134. [Full Text] [PDF]
|
|
|
|
|
|
H. Deguchi, N. M. Pecheniuk, D. J. Elias, P. M. Averell, and J. H. Griffin High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men Circulation, August 9, 2005; 112(6): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Zern, R. J. Wood, C. Greene, K. L. West, Y. Liu, D. Aggarwal, N. S. Shachter, and M. L. Fernandez Grape Polyphenols Exert a Cardioprotective Effect in Pre- and Postmenopausal Women by Lowering Plasma Lipids and Reducing Oxidative Stress J. Nutr., August 1, 2005; 135(8): 1911 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barter The role of HDL-cholesterol in preventing atherosclerotic disease Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F4 - F8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Lewis and D. J. Rader New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport Circ. Res., June 24, 2005; 96(12): 1221 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Coutinho, R. R. Singaraja, M. Kang, D. J. Arenillas, L. N. Bertram, N. Bissada, B. Staels, J.-C. Fruchart, C. Fievet, A. M. Joseph-George, et al. Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis J. Lipid Res., June 1, 2005; 46(6): 1113 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Nicholls and S. E. Nissen Strategies to promote HDL-C: an emerging therapeutic target Eur. Heart J., May 1, 2005; 26(9): 853 - 855. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Brousseau, M. R. Diffenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Bjorkhem, B. Angelin, et al. Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion Arterioscler Thromb Vasc Biol, May 1, 2005; 25(5): 1057 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Lloyd, M. E. Lira, L. S. Wood, L. K. Durham, T. B. Freeman, G. M. Preston, X. Qiu, E. Sugarman, P. Bonnette, A. Lanzetti, et al. Cholesteryl Ester Transfer Protein Variants Have Differential Stability but Uniform Inhibition by Torcetrapib J. Biol. Chem., April 15, 2005; 280(15): 14918 - 14922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Forrester, R. Makkar, and P.K. Shah Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians Circulation, April 12, 2005; 111(14): 1847 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.M. Boekholdt, F.M. Sacks, J.W. Jukema, J. Shepherd, D.J. Freeman, A.D. McMahon, F. Cambien, V. Nicaud, G.J. de Grooth, P.J. Talmud, et al. Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects Circulation, January 25, 2005; 111(3): 278 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-H. Chung, B. S. Cho, P. Liang, S. Doran, L. Osterlund, R. A Oster, B. Darnell, and F. Franklin Contribution of postprandial lipemia to the dietary fat-mediated changes in endogenous lipoprotein-cholesterol concentrations in humans Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. de Grooth, A. H. E. M. Klerkx, E. S. G. Stroes, A. F. H. Stalenhoef, J. J. P. Kastelein, and J. A. Kuivenhoven A review of CETP and its relation to atherosclerosis J. Lipid Res., November 1, 2004; 45(11): 1967 - 1974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Brown, A. Gauthier, R. J. Parks, R. McPherson, D. L. Sparks, J. R. Schultz, and Z. Yao Severe Hypoalphalipoproteinemia in Mice Expressing Human Hepatic Lipase Deficient in Binding to Heparan Sulfate Proteoglycan J. Biol. Chem., October 8, 2004; 279(41): 42403 - 42409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Brewer Jr, A. T. Remaley, E. B. Neufeld, F. Basso, and C. Joyce Regulation of Plasma High-Density Lipoprotein Levels by the ABCA1 Transporter and the Emerging Role of High-Density Lipoprotein in the Treatment of Cardiovascular Disease Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1755 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhang, P. Fan, E. Shimoji, H. Xu, K. Takeuchi, C. Bian, and K. Saku Inhibition of Cholesteryl Ester Transfer Protein Activity by JTT-705 Increases Apolipoprotein E-Containing High-Density Lipoprotein and Favorably Affects the Function and Enzyme Composition of High-Density Lipoprotein in Rabbits Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1910 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Wolfe and D. J. Rader Cholesteryl Ester Transfer Protein and Coronary Artery Disease: An Observation With Therapeutic Implications Circulation, September 14, 2004; 110(11): 1338 - 1340. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Boekholdt, J.-A. Kuivenhoven, N. J. Wareham, R. J.G. Peters, J. W. Jukema, R. Luben, S. A. Bingham, N. E. Day, J. J.P. Kastelein, and K.-T. Khaw Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study Circulation, September 14, 2004; 110(11): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-H. Chung, P. Liang, S. Doran, B. H. S. Cho, and F. Franklin Postprandial chylomicrons: potent vehicles for transporting cholesterol from endogenous LDL+HDL and cell membranes to the liver via LCAT and CETP J. Lipid Res., July 1, 2004; 45(7): 1242 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Witte, M. R. Taskinen, H. Perttunen-Nio, A. van Tol, S. Livingstone, and H. M. Colhoun Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis J. Lipid Res., June 1, 2004; 45(6): 1069 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, F. Sadeghi-Niaraki, and A. van Tol Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins J. Lipid Res., May 1, 2004; 45(5): 805 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Brewer Jr. Increasing HDL Cholesterol Levels N. Engl. J. Med., April 8, 2004; 350(15): 1491 - 1494. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Brousseau, E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol N. Engl. J. Med., April 8, 2004; 350(15): 1505 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Masson, B. Staels, T. Gautier, C. Desrumaux, A. Athias, N. Le Guern, M. Schneider, Z. Zak, L. Dumont, V. Deckert, et al. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse J. Lipid Res., March 1, 2004; 45(3): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Brewer Jr. High-Density Lipoproteins: A New Potential Therapeutic Target for the Prevention of Cardiovascular Disease Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 387 - 391. [Full Text]
|
|
|
|
|
|
R. W. Clark, T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitey, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, et al. Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 490 - 497. [Abstract] [Full Text]
|
|
|
|
|
|
N. Barzilai, G. Atzmon, C. Schechter, R. Lipton, and A. R. Shuldiner Genetic Factors in Exceptional Longevity--Reply JAMA, February 25, 2004; 291(8): 942 - 943. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Rader High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis JAMA, November 5, 2003; 290(17): 2322 - 2324. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Berti, A. C. Casquero, P. R. Patricio, E. J. B. Bighetti, E. M. Carneiro, A. C. Boschero, and H. C. F. Oliveira Cholesteryl ester transfer protein expression is down-regulated in hyperinsulinemic transgenic mice J. Lipid Res., October 1, 2003; 44(10): 1870 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuchel and D. J. Rader Genetics of Increased HDL Cholesterol Levels: Insights Into the Relationship Between HDL Metabolism and Atherosclerosis Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1710 - 1712. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Boekholdt and J. F. Thompson Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J. Lipid Res., July 1, 2003; 44(6): 1080 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Parini and L. L. Rudel Is There a Need for Cholesteryl Ester Transfer Protein Inhibition? Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 374 - 375. [Full Text] [PDF]
|
|